Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major...

Full description

Bibliographic Details
Main Authors:	Herjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, Maria Slootweg, Harm H E van Melick, Erik P M Roos, Diederik M Somford, Yvette Zimmerman, Iman J Schultz, Noel W Clarke, R Jeroen A van Moorselaar, Frans M J Debruyne
Format:	Article
Language:	English
Published:	Bioscientifica 2022-11-01
Series:	Endocrine Connections
Subjects:	androgen deprivation therapy (adt) bone health estrogen therapy (et) transdermal estradiol (te2) estetrol (e4)
Online Access:	https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0182.xml

Similar Items

Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
by: Yvette Zimmerman, et al.
Published: (2022-11-01)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
by: Herjan J.T. Coelingh Bennink, et al.
Published: (2021-06-01)

Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review
by: Herjan J.T. Coelingh Bennink, et al.
Published: (2022-12-01)

Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview
by: David F. Archer, et al.
Published: (2022-08-01)

Estetrol: a new estrogen component in combined oral contraceptives: A review
by: Aida U. Hamadyanova, et al.
Published: (2023-01-01)

ESTETROL: DESDE UN ESTRÓGENO FETAL HASTA EL TRATAMIENTO DE LA MENOPAUSIA
by: Marcelo Bianchi P
Published: (2009-01-01)

Neuroprotective effects of estetrol in combined oral contraceptives: A review
by: Mekan R. Orazov, et al.
Published: (2023-07-01)

Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature
by: Rodrigo Cartes, et al.
Published: (2023-06-01)

The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation
by: Anne Abot, et al.
Published: (2014-10-01)

Estetrol Increases Progesterone Genetic Response without Triggering Common Estrogenic Effects in Endometriotic Cell Lines and Primary Cultures
by: Daniel Patiño-García, et al.
Published: (2023-04-01)

An insight into the use of estetrol-drospirenone as effective oral contraceptive
by: Himanshu Chaudhry, et al.
Published: (2023-03-01)

Effect of an estetrol/drospirenone contraceptive on sexual function in women of reproductive age
by: Mekan R. Orazov, et al.
Published: (2023-04-01)

Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer
by: Anne Gallez, et al.
Published: (2021-05-01)

Structure and Thermal Stability of Two Estetrol Solvates
by: Magda Monari, et al.
Published: (2023-08-01)

The effect of hormonal contraception on the risk of breast cancer: A review
by: Mariia V. Iurova, et al.
Published: (2023-08-01)

The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells
by: Qianyao Tang, et al.
Published: (2021-10-01)

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial
by: J. Janssen, et al.
Published: (2022-05-01)

Comparison of Estetrol Exposure between Women and Mice to Model Preclinical Experiments and Anticipate Human Treatment
by: Anne Gallez, et al.
Published: (2023-06-01)

The benefits of estetrol addition to drospirenone for contraception
by: Jean Michel Foidart, PhD, MD, et al.
Published: (2023-11-01)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
by: Hengping Li, et al.
Published: (2022-08-01)

Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue
by: Ulrich Sommer, et al.
Published: (2022-06-01)

Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
by: Moyad MA, et al.
Published: (2016-08-01)

Estetrol improves quality of life in advanced castration-sensitive prostate cancer: A randomized clinical trial
by: R.J.A. Van Moorselaar, et al.
Published: (2022-08-01)

A tumor cell specific Zona Pellucida glycoprotein 3 RNA transcript encodes an intracellular cancer antigen
by: Iman J. Schultz, et al.
Published: (2023-12-01)

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl)
by: Huub H. van Rossum, et al.
Published: (2023-02-01)

EFFECTS OF ESTETROL ON MIGRATION AND INVASION IN T47-D BREAST CANCER CELLS THROUGH THE ACTIN CYTOSKELETON
by: Maria Silvia eGiretti, et al.
Published: (2014-05-01)

Review of Current Treatment Intensification Strategies for Prostate Cancer Patients
by: Sobia Wasim, et al.
Published: (2023-11-01)

Estetrol: A New Choice for Contraception
by: Franca Fruzzetti, et al.
Published: (2021-11-01)

Complex questions about combined hormonal contraception: A review
by: Vera N. Prilepskaya, et al.
Published: (2023-07-01)

Target expression is a relevant factor in synthetic lethal screens
by: Iman J. Schultz, et al.
Published: (2022-08-01)

Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review
by: Marta Stelmach-Mardas, et al.
Published: (2024-02-01)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
by: Lindsey Gallagher, et al.
Published: (2023-10-01)

TREATMENT OF ELDERLY PATIENTS WITH DORSOPATHY
by: P. R. KAMCHATNOV, et al.
Published: (2016-12-01)

Transdermal estradiol as a novel treatment for Peyronie's disease: A case report
by: Jessie Thuswaldner
Published: (2020-09-01)

Transdermal estrogen in women of reproductive age (for the practitioner's aid)
by: E A Mezhevitinova
Published: (2016-04-01)

Trans dermal estrogen (oestrogel) for endometrial preparation in freeze embryo transfer cycle: An RCT
by: Ensieh Shahrokh Tehraninejad, et al.
Published: (2018-02-01)

Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study
by: Vishnu Murthy, et al.
Published: (2023-10-01)

Efficacy of Green Oxide Nanofluids as Potential Dispersants for Asphaltene in Iraqi Crudes, Experimental, Tunning and Statistical Analysis
by: Dana Khidhir, et al.
Published: (2022-09-01)

Impact of neoadjuvant relugolix on patient-reported sexual function and bother
by: Jessica Y. Hsueh, et al.
Published: (2024-04-01)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
by: Renée de Leeuw, et al.
Published: (2020-10-01)